-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Benzinga·11/12/2026 14:41:39
Listen to the news
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $11 to $12.